Rak moczownika – mozliwosci skutecznego leczenia


Author(s): Marta Biedka, Tamara Kuzba-Kryszak, Adrianna Makarewicz

The estimated incidence of urachal carcinoma in the general population is reported to be 1 in 5 million individuals with a peak incidence at 40-70 years of age, two thirds of patients being men. Urachal carcinoma may arise from any of the segments of persisting urachal remnants. Histopathologically, most urachal carcinomas are adenocarcinomas (accounting for 90%). The recommended treatment is major surgery – wide en bloc resection of the tumour with the urachus and the adjacent organs: the bladder, bilateral pelvic lymph nodes, brown tissue, surrounding ligaments, the sigmoid, the umbilicus and part of the anterior abdominal wall. The attempts of combining surgery with radiotherapy do not deliver the anticipated results. Similarly, minimal or no benefit has been reported for systemic therapy. In conclusion, we wish to emphasise the significance of the need for a careful preliminary analysis of urachal carcinoma patients and the pivotal role of radical surgery in the successful treatment of this disease.

Share this article

Editors List

  • Osamu Tanaka

    Osamu Tanaka
    Assistant Professor,
    Department of Radiation Oncology
    Asahi University Hospital
    Gifu city, Gifu, Japan

  • Maher Abdel Fattah Al-Shayeb

    Department of Surgical Sciences, Ajman University, UAE

  • Andrzej Zdziennicki

    Institute of Gynecology and Obstetrics, Medical University of Lodz, I Clinic of Gynecology and Gynecological Oncology (Lodz, Poland)

  • Krzysztof Urbanski

    Head of the Oncology Gynecology Clinic, Oncology Center - Instytut im. Maria Sklodowska Curie, Department in Krakow (Krakow, Poland)

  • Andrzej Szawlowski

    Klinika Nowotworow Gornego Odcinka Uklad Digestii, Oncology Center - Institute (Warsaw, Poland)